Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2019 May 3;23(1):66–73. doi: 10.1038/s41391-019-0152-3

Table 4:

Proportional hazards model with change in serum androgen predicting progression-free survival

Variable Hazard Ratio (95% CI) p-value
LDH> 1ULN
(yes vs. no)		 1.38 (1.13–1.70) 0.002
Opioid use
(yes vs. no)		 1.09 (0.88–1.33) 0.435
Performance status
(1,2 vs. 0)		 1.09 (0.92–1.29) 0.340
Bone/Bone+LN vs LN 1.19 (0.85–1.65) 0.306
Any visceral site vs LN 1.37 (0.94–2.00) 0.101
PSA 1.00 (1.00–1.00) 0.004
Hemoglobin 0.96 (0.90–1.02) 0.255
Alkaline Phosphate 1.00 (1.00–1.027) 0.607
Albumin 1.00 (0.94–1.07) 0.954
T change
(6-weeks/Baseline ratio)		 1.01 (1.00–1.02) 0.128
A change
(6-weeks/Baseline ratio)		 0.93 (0.85–1.01) 0.089
DHEA change (6-weeks/Baseline ratio) 0.98 (0.93–1.04) 0.585